The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care

BACKGROUND: The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an assoc...

Descripción completa

Detalles Bibliográficos
Autores principales: Saya, Sibel, Chondros, Patty, Abela, Anastasia, Mihalopolous, Cathrine, Chatterton, Mary Lou, Gunn, Jane, Chen, Timothy F., Polasek, Thomas M., Dettmann, Elise, Brooks, Rachel, King, Michelle, Spencer, Luke, Alphonse, Pavithran, Milton, Shakira, Ramsay, Georgia, Siviour, Zoe, Liew, Jamie, Ly, Philip, Thoenig, Matthew, Seychell, Raushaan, La Rocca, Floriana, Hesson, Luke B., Mejias, Nydia, Sivertsen, Terri, Galea, Melanie Anne, Bousman, Chad, Emery, Jon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197047/
https://www.ncbi.nlm.nih.gov/pubmed/37208772
http://dx.doi.org/10.1186/s13063-023-07361-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10197047/
https://www.ncbi.nlm.nih.gov/pubmed/37208772
http://dx.doi.org/10.1186/s13063-023-07361-6

Ejemplares similares